News from decision resources group A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Oct 30, 2014, 13:00 ET
Decision Resources Group Logo.

In 2023, Medivation/Astellas Pharma's Xtandi Will Be the Top-Selling Agent in the Prostate Cancer Market Across the United States, Europe, and Japan

 Decision Resources Group finds that Medivation/Astellas Pharma's Xtandi will be the sales-leading agent across the world's major markets for...

Oct 30, 2014, 12:45 ET
Decision Resources Group Logo.

Bristol-Myers Squibb/Otsuka's Abilify is a Preferred Branded Agent for the Treatment of Schizophrenia, According to Surveyed U.S. Psychiatrists and Payers

Decision Resources Group finds that Bristol-Myers Squibb/Otsuka's Abilify is the branded agent with the highest patient share in schizophrenia,...

Oct 30, 2014, 10:00 ET
Decision Resources Group Logo.

U.S. Breast Implant and Reconstructive Device Market Will Grow Modestly in the Next Few Years, While European Market Will Decline Until the Economy Recovers

Decision Resources Group finds that the United States and European breast implant and reconstructive device market will expand modestly through...

Oct 29, 2014, 14:07 ET
Decision Resources Group Logo.

U.S. Physicians and Payers are Generally Positive About the Efficacy of Pfizer's Xeljanz for Treating RA But They Have Mixed Views About Its Effect on Structural Damage and Safety

 Decision Resources Group finds that although 80 percent of surveyed rheumatologists currently prescribe Pfizer's Xeljanz for the treatment of...

Oct 29, 2014, 12:00 ET
Decision Resources Group Logo.

The Market for Non-Small-Cell Lung Cancer Will Grow to $8.5 Billion in 2023, Driven by the Entry of Thirteen Novel Drugs

 Decision Resources Group finds that the entry of 13 novel therapies into the non-small-cell lung cancer (NSCLC) market will drive the market's...

Oct 29, 2014, 10:00 ET
Decision Resources Group Logo.

U.S. Surgical Hemostat, Internal Tissue Sealant and Adhesion Barrier Market to Reach Nearly $2.9 Billion

 Decision Resources Group finds that the United States market for surgical hemostats, internal tissue sealants and adhesion barriers will grow...

Oct 27, 2014, 10:00 ET
Decision Resources Group Logo.

Physician-Reported Patient Share for Bayer's Eylea in the EU5 Wet Age-Related Macular Degeneration Market Has Increased Significantly Over the Past Year

 Decision Resources Group finds that retinal specialists in the EU5 (France, Germany, Italy, Spain, and the United Kingdom) report patient...

Oct 23, 2014, 14:00 ET
Decision Resources Group Logo

Opposing Market Forces Lead to Limited Growth of the Acute Pain Market Through 2023

 Decision Resources Group finds that the acute pain market will grow minimally from $12.7 billion in 2013 to $13.3 billion in 2023 across the...

Oct 23, 2014, 12:00 ET
Decision Resources Group Logo.

Abilify is the Most Commonly Prescribed Antipsychotic Drug Among Newly Diagnosed Bipolar Disorder Patients in the United States

Decision Resources Group finds that, through analysis of U.S. longitudinal patient-level claims data, Abilify (Bristol-Myers...

Oct 23, 2014, 11:30 ET
Decision Resources Group Logo.

Industry-Leading Speakers Present Next Month at Managed Care Account Management Training in San Francisco

Decision Resources Group is pleased to host seven expert speakers who will deliver comprehensive training presentations during its managed care...

Oct 21, 2014, 12:00 ET
Decision Resources Group Logo.

Biomarker-Driven Prescribing is Currently the Standard-of-Care for HER2-Positive Breast Cancer and EGFR-Mutation Positive NSCLC, According to Oncologists in Argentina and Mexico

Decision Resources Group finds that the majority of surveyed oncologists in Argentina and Mexico are primarily prescribing biomarker-driven agents...

Oct 20, 2014, 14:00 ET
Decision Resources Group Logo.

The Age-Related Macular Degeneration Drug Market Will Grow to Nearly $9 Billion in 2023, Fueled in Part by the Anticipated Launch of the First Therapies for Geographic Atrophy

Decision Resources Group finds that the market for age-related macular degeneration (AMD) pharmacotherapies will expand 6 percent annually to reach...

Oct 20, 2014, 12:30 ET
Decision Resources Group Logo.

Asia Pacific Gastrointestinal Endoscopy Device Market Will Grow at 9 Percent Annually Through 2023

Decision Resources Group finds that the Asia Pacific gastrointestinal (GI) endoscopy device market will grow strongly through 2023 at a 9 percent...

Oct 16, 2014, 13:15 ET
Decision Resources Group Logo.

Despite Generic Erosion of Several Key Brands, the Renal Cell Carcinoma (RCC) Market Will Experience Modest Growth through 2023

Decision Resources Group finds that the market for renal cell carcinoma (RCC) therapies will grow to approximately $2.5 billion by 2023, despite...

Oct 16, 2014, 10:00 ET
Decision Resources Group Logo

Physicians in Both South Korea and Taiwan Anticipate Healthy Uptake of the Emerging SGLT-2 Inhibitors for Type 2 Diabetes Treatment, but Payers Predict a Tough P&R Environment

Decision Resources Group finds that, for the treatment of type 2 diabetes, over 90 percent of surveyed physicians in South Korea and Taiwan...

Oct 15, 2014, 12:00 ET
Decision Resources Group Logo.

In the Face of Sales Erosion of Key Brands by Novel Formulations, GlaxoSmithKline/Theravance's LABA/LAMA Anoro Will Become the Leading COPD Agent in 2023

Decision Resources Group finds that the emergence of the long-acting beta2 agonist (LABA)/long-acting muscarinic antagonist (LAMA) drug class will...

Oct 15, 2014, 11:00 ET
Decision Resources Group Logo.

While Rheumatologists Would Welcome Novel Biologics for the Treatment of Systemic Lupus Erythematosus (SLE), Reimbursement Challenges Are Expected

 Decision Resources Group finds that although use of biologics in SLE has increased in the past three years, largely due to uptake of...

Oct 15, 2014, 10:00 ET
Decision Resources Group Logo.

U.S. Reprocessed Device Market Will Reach Over $680 Million by 2023

 Decision Resources Group finds that the market for reprocessed devices in the United States will undergo robust growth, reaching a value of...

Oct 15, 2014, 09:00 ET
Decision Resources Group Logo.

Decision Resources Group Announces Its Spring Managed Markets Summit to be Held in New Orleans in March, 2015

 Decision Resources Group's 2015 Spring Managed Markets Summit (MMS) is a three-day conference dedicated to educating pharmaceutical and...

Oct 14, 2014, 11:32 ET
Decision Resources Group Logo

The Launch of New Therapies to Treat Niche Populations Will Drive 5 Percent Annual Sales Growth in the Parkinson's Disease (PD) Drug Market from 2013 to 2023

BURLINGTON, Mass., Oct. 14, 2014 /PRNewswire/ --  Decision Resources Group finds that the Parkinson's disease (PD) pharmacotherapy market...